Data updated: Mar 10, 2026
RESCRIPTOR
DELAVIRDINE MESYLATE
Approved 1997-04-04
2
Indications
--
Phase 3 Trials
1
Priority Reviews
28
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1997-04-04
- Routes
- ORAL
- Dosage Forms
- TABLET
RESCRIPTOR Approval History
Loading approval history...
What RESCRIPTOR Treats
2 FDA approvalsOriginally approved for its first indication in 1997 . Covers 2 distinct patient populations.
- Other (2)
Other
(2 approvals)- • Approved indication (Apr 1997) Priority
- • Approved indication (May 2001)Label
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RESCRIPTOR FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.